Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib Plus Docetaxel in NFE2L2/KEAP1-Positive Squamous Cell Lung Cancer (LUNG-MAP S1900D)
NCT04267913Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of sapanisertib in squamous cell carcinoma of the lung (LSCC), sponsored by SWOG Cancer Research Network. Planned start Sep 2020; status: withdrawn.
02
Drugs
sapanisertib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT04267913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267913.